Guidance

Concomitant use of NUSTENDI®/NILEMDO® with simvastatin >40 mg daily is contraindicated; please refer to the relevant SmPC for more information.^3,4

The NICE NG238 and AAC guidance covers lipid management and treatment targets for primary and secondary prevention of CVD.^1,2

Concomitant use of NUSTENDI®/NILEMDO® with simvastatin >40 mg daily is contraindicated; please refer to the relevant SmPC for more information.^3,4

To support ambitions to reduce premature mortality from heart disease or stroke by 25% within a decade, the QOF 2025/26 has introduced significant changes focused on CVD prevention. This comprises the reallocation of 141 QOF points (worth £198 million) across nine CVD prevention indicators, including its two CHOL indicators.⁵

Concomitant use of NUSTENDI®/NILEMDO® with simvastatin >40 mg daily is contraindicated; please refer to the relevant SmPC for more information.^3,4

The CVD prevention scheme focuses on identifying patients at risk of developing CVD, thereby helping to reduce the risk of its onset.⁷

Summary of the key information only, for full information please visit Health Improvement Scotland Right Decision Service website.

The Health Improvement Scotland Right Decision Service

The Health Improvement Scotland Right Decision Service has a ‘Treat to Target’ of <1.8 mmol/L LDL-C or equivalent of <2.5 mmol/L non-HDL for secondary prevention.⁸

*ASSIGN is a CV risk score (0-100) which estimates the 10-year percentage risk of developing CVD for individuals in Scotland who do not currently have a diagnosis of CVD. ‘High-risk’ score ≥10 should be offered targeted risk reduction advice and treatments in line with current SIGN guidelines.⁹